Syndrome News and Research

RSS

Study examines efficacy Pfizer-BioNTech vaccine among USAF Academy Cadets

A new study published on the medRxiv* preprint server has estimated the effectiveness of vaccines in preventing COVID-19 as a function of time since vaccination.

3 Aug 2021

Unvaccinated and vaccinated have similar viral load in communities high in SARS-CoV-2 delta

The findings reveal that vaccinated and unvaccinated individuals exhibit similar viral loads following delta infection and that vaccine breakthrough cases have the potential to transmit infection to others. The study is currently available on the medRxiv* preprint server.

3 Aug 2021

National Qatari study shows vaccination reduces risk of spreading SARS-CoV-2 infection

A team of scientists from Qatar and the United States has recently studied the viral transmission potential of individuals with primary severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, reinfection, or vaccine breakthrough infection.

2 Aug 2021

CDC scientists model the most efficient physical barrier against SARS-CoV-2 for worker protection

Size doesn’t matter — when it comes to physical barriers in the workplace. A new Centers for Disease Control and Prevention (CDC) study found larger barriers were not statistically better than smaller physical barriers in protecting against severe acute respiratory syndrome 2 (SARS-CoV-2).

2 Aug 2021

Study shows efficacy of Pfizer-BioNTech and Moderna vaccines against SARS-CoV-2 delta variant

Researchers in Singapore have conducted a study showing that the messenger RNA- (mRNA) based coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna are highly effective at protecting against symptomatic and severe disease following infection with the rapidly spreading B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Aug 2021

Cancer vaccine reduces tumor burden, improves survival in animal model of Lynch syndrome

A new strategy for developing vaccines against cancer showed promise in a proof-of-concept study led by scientists at Weill Cornell Medicine, NewYork-Presbyterian and Heidelberg University Hospital.

2 Aug 2021

Pfizer moves towards an oral anti-COVID-19 therapy

Researchers in the United States have described a novel antiviral agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently being evaluated in clinical trials as a treatment for coronavirus disease 2019 (COVID-19).

2 Aug 2021

Researchers discover titanium oxide nanoparticle that recognizes SARS-CoV-2’s non-structural protein 1

A pioneering study reports on the interaction of a tailored titanium oxide nanoparticle (NP) with the full-length SARS-CoV-2 non-structural protein 1 (nsp1). This should be of value in developing new therapeutic tools against coronaviruses that act by targeting their proteins. It could also help map the structure of activated proteins.

2 Aug 2021

Polyuridine sequence of mouse coronavirus can be targeted to prevent host cell death

A new study reports the use of a modified deoxyribonucleic acid (DNA) oligonucleotide that has a 3’ polyadenine (polyA) tail to bind to the 5’-polyU tract in the mouse coronavirus (MHV-A59). Treatment of mouse cells infected with MHV-A59 with this molecule led to a marked reduction in cell deaths.

2 Aug 2021

Could novel biosensors facilitate SARS-CoV-2 antiviral drug research?

An intriguing new study presents a novel approach to biosensor-based evaluation of promising drugs that could inhibit the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via its 3C-like protease (3CLpro), a viral protease.

2 Aug 2021

Intradermal administration of low-dose mRNA COVID-19 vaccine induces strong immune response, study finds

Scientists in the Netherlands recently conducted an open-level, randomized-controlled trial to evaluate the safety and immunogenicity of fractional intradermal doses of the mRNA-based COVID-19 vaccine mRNA-1273 (Moderna). The trial findings reveal that the fractional dose regimen of the Moderna vaccine is well tolerated and safe and is capable of inducing robust antibody responses in vaccine recipients. The study is currently available on the medRxiv* preprint server.

2 Aug 2021

Scientists develop a potent peptide inhibitor of SARS-CoV-2 in vitro

In a recently published article in the journal Drugs in R&D, scientists have described the development and validation of a 13-amino acid peptide inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Aug 2021

Improving patient monitoring and alarm management strategies in burn intensive care units

The combination of injured skin, specialized medical care and the need to continuously monitor critically ill patients with burn injuries can make alarm management a significant challenge for burn units.

2 Aug 2021

Study examined 1,497 full-vaccinated healthcare workers for breakthrough infections

A new study published in The New England Journal of Medicine found that in a very small number of cases, people with breakthrough infections might suffer long-lasting COVID-19 symptoms.

2 Aug 2021

Older adults with prior SARS-CoV-2 infection benefit from two doses of Pfizer/BioNTech vaccine

The study by researchers from the Ministry of Health, Madrid, Spain, published in the Center of Disease Control and Prevention’s journal Emerging Infectious Diseases, suggests that long-term care facility residents with prior SARS-CoV-2 infection benefit from full vaccination with the Pfizer/BioNTech (BNT162b2) vaccine.

2 Aug 2021

SARS-CoV-2 Q493R protein mutation shows resistance to monoclonal antibodies

The Centers for Disease Control and Prevention (CDC) issued a letter detailing a case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised patient who did not respond well to monoclonal antibody treatment. The resistance to treatment stemmed from an escape mutation on the spike protein known as Q4923R.

2 Aug 2021

Public and private SARS-CoV-2 T cell receptors may be crucial for pan-coronavirus vaccines

Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.

2 Aug 2021

Oh deer! Antibodies to SARS-CoV-2 detected in 40% of wild white-tailed deer in four U.S. states

Researchers conducting a serosurveillance study of a North American deer species have provided evidence of exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among the animals across four U.S. states.

1 Aug 2021

Antibody responses following SARS-CoV-2 infection more potent than vaccine-elicited ones

Researchers in the United States have conducted a study showing the difference in antibody evolution following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between people who have not previously been infected with the virus and those who have.

1 Aug 2021

Fighting SARS-CoV-2 with nanomedicine

Published in the Journal of Controlled Release, researchers from the German University in Cairo, and the University of Cologne, looked into nano-reformulation of repurposed antiviral and immune-modulating drugs for inhalation therapy against COVID-19. In addition, they focused on how nanomedicine could address the limitations of current therapeutics, enhancing the efficacy, specificity, and safety of such drugs.

1 Aug 2021

Syndrome News and Research

Study examines efficacy Pfizer-BioNTech vaccine among USAF Academy Cadets

Unvaccinated and vaccinated have similar viral load in communities high in SARS-CoV-2 delta

National Qatari study shows vaccination reduces risk of spreading SARS-CoV-2 infection

CDC scientists model the most efficient physical barrier against SARS-CoV-2 for worker protection

Study shows efficacy of Pfizer-BioNTech and Moderna vaccines against SARS-CoV-2 delta variant

Cancer vaccine reduces tumor burden, improves survival in animal model of Lynch syndrome

Pfizer moves towards an oral anti-COVID-19 therapy

Researchers discover titanium oxide nanoparticle that recognizes SARS-CoV-2’s non-structural protein 1

Polyuridine sequence of mouse coronavirus can be targeted to prevent host cell death

Could novel biosensors facilitate SARS-CoV-2 antiviral drug research?

Intradermal administration of low-dose mRNA COVID-19 vaccine induces strong immune response, study finds

Scientists develop a potent peptide inhibitor of SARS-CoV-2 in vitro

Improving patient monitoring and alarm management strategies in burn intensive care units

Study examined 1,497 full-vaccinated healthcare workers for breakthrough infections

Older adults with prior SARS-CoV-2 infection benefit from two doses of Pfizer/BioNTech vaccine

SARS-CoV-2 Q493R protein mutation shows resistance to monoclonal antibodies

Public and private SARS-CoV-2 T cell receptors may be crucial for pan-coronavirus vaccines

Oh deer! Antibodies to SARS-CoV-2 detected in 40% of wild white-tailed deer in four U.S. states

Antibody responses following SARS-CoV-2 infection more potent than vaccine-elicited ones

Fighting SARS-CoV-2 with nanomedicine

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News